Literature DB >> 12468017

Small animal PET.

Ralph Myers1, Susan Hume.   

Abstract

Positron emission tomography (PET) has well-established strengths which are commonly exploited in human clinical research. Not least of these are its dynamic and quantitative capabilities. The recent growth in small animal PET, spurred on by technological developments and an interest in the application of imaging to the field of genomics in mice, has seen impressive improvements in image spatial resolution. The availability of commercial small animal PET scanners has meant a broadening of the user base away from PET development environments and into experimental laboratories. This paper will review these developments and assess the impact on overall data quality.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12468017     DOI： 10.1016/s0924-977x(02)00103-7

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN： 0924-977X            Impact factor:   4.600


  11 in total

Review 1.  Techniques for brain imaging in vivo.

Authors:  Monica Garcia-Alloza; Brian J Bacskai
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

Review 2.  Small animal PET: aspects of performance assessment.

Authors:  Simone Weber; Andreas Bauer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-10-02       Impact factor: 9.236

3.  NanoPET imaging of [(18)F]fluoromisonidazole uptake in experimental mouse tumours.

Authors:  Matthias T Wyss; Michael Honer; Pius A Schubiger; Simon M Ametamey
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-10-29       Impact factor: 9.236

4.  Further evaluation of the carbon11-labeled D(2/3) agonist PET radiotracer PHNO: reproducibility in tracer characteristics and characterization of extrastriatal binding.

Authors:  Alice Egerton; Ella Hirani; Rabia Ahmad; David R Turton; Diana Brickute; Lula Rosso; Oliver D Howes; Sajinder K Luthra; Paul M Grasby
Journal:  Synapse       Date:  2010-04       Impact factor: 2.562

5.  Acute effect of the anti-addiction drug bupropion on extracellular dopamine concentrations in the human striatum: an [11C]raclopride PET study.

Authors:  Alice Egerton; John P Shotbolt; Paul R A Stokes; Ella Hirani; Rabia Ahmad; Julia M Lappin; Suzanne J Reeves; Mitul A Mehta; Oliver D Howes; Paul M Grasby
Journal:  Neuroimage       Date:  2009-12-05       Impact factor: 6.556

6.  A rat head holder for simultaneous scanning of two rats in small animal PET scanners: design, construction, feasibility testing and kinetic validation.

Authors:  Tee Ean Cheng; Karmen K Yoder; Marc D Normandin; Shannon L Risacher; Alexander K Converse; Joseph A Hampel; Michael A Miller; Evan D Morris
Journal:  J Neurosci Methods       Date:  2008-09-07       Impact factor: 2.390

7.  Accuracy and reproducibility of tumor positioning during prolonged and multi-modality animal imaging studies.

Authors:  Mutian Zhang; Minming Huang; Carl Le; Pat B Zanzonico; Filip Claus; Katherine S Kolbert; Kyle Martin; C Clifton Ling; Jason A Koutcher; John L Humm
Journal:  Phys Med Biol       Date:  2008-09-30       Impact factor: 3.609

8.  Modulation of striatal dopamine release by 5-HT2A and 5-HT2C receptor antagonists: [11C]raclopride PET studies in the rat.

Authors:  Alice Egerton; Rabia Ahmad; Ella Hirani; Paul M Grasby
Journal:  Psychopharmacology (Berl)       Date:  2008-07-03       Impact factor: 4.530

9.  Influence of simultaneous targeting of the bone morphogenetic protein pathway and RANK/RANKL axis in osteolytic prostate cancer lesion in bone.

Authors:  Mandeep S Virk; Frank A Petrigliano; Nancy Q Liu; Arion F Chatziioannou; David Stout; Christine O Kang; William C Dougall; Jay R Lieberman
Journal:  Bone       Date:  2008-09-26       Impact factor: 4.398

Review 10.  The role of positron emission tomography in the discovery and development of new drugs; as studied in laboratory animals.

Authors:  Peter Roselt; Steven Meikle; Michael Kassiou
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2004 Jan-Mar       Impact factor: 2.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.